(September 15, 2015, 2:19 PM EDT) -- WASHINGTON, D.C. — Two members of the House Energy and Commerce Committee on Sept. 2 asked the Food and Drug Administration what steps, if any, the agency is taking to address safety and medical errors related to the anticoagulants Coumadin and warfarin....